Selvax Cancer Immunotherapy | The Selvax Team
143
page-template,page-template-full_width,page-template-full_width-php,page,page-id-143,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-10.1.2,wpb-js-composer js-comp-ver-5.3,vc_responsive
 

The Selvax Team

Kylie Brierty

Chairperson

Kylie Brierty is a businesswoman and supporter of medical innovation. She was a principal and director of a large private civil contracting company in WA, served as President of the Civil Contractors Federation (WA) and was a member of the Main Roads Industry Advisory Group. She has been a major shareholder of Selvax since its formation and a supporter of medical research at Curtin University.

Ron Wise

Co Founder and Director

Ron has a PhD in immunology from UWA and undertook postdoctoral research at Stanford University. He is a co founder and director of Selvax and a major shareholder in the company.

Tony Fitzgerald

Director

Tony is a co founder of Selvax. He practiced law before moving into the life sciences sector where he has undertaken numerous technology licensing and collaborative research transactions and company start ups.

Russell Nicholls

Director

Russell is Deputy Director, IP Commercialisation at Curtin University. He is a registered technology transfer professional and graduate of the Australian Institute of Company Directors.

Delia Nelson BSc PhD

Chief Scientific Officer

Delia is a Professor in the School of Pharmacy and Biomedical Sciences at Curtin University. She has over twenty years research experience in tumour immunology and ageing and is a co founder of Selvax.

Stephen Proksch BSc MBA

Research Coordinator

Stephen is a biomedical research scientist and MBA graduate with over ten years experience working in the biotechnology sector. His major areas of expertise are immunology and molecular genetics.

Scientific Advisory Board

Dr Leanna Read

Dr Leanna Read has recently completed a four year term as Chief Scientist for South Australia. She has broad-ranging executive, board and investment experience in technology-based enterprises, particularly biotechnology and cancer immunology.

 

As CEO and Chair of the CRC for Cell Therapy Manufacturing (CTM CRC) until October 2019, she had oversight of research programs with a strong cancer immunology focus. She has an ongoing role as chair of CTM CRC’s spin-out company, Carina Biotech Pty Ltd, which is developing an effective broad spectrum chimeric antigen receptor T cell (CAR-T) therapy to treat solid cancers.

 

Dr Read brings extensive experience on boards that address scientific innovation across government, industry and academic sectors and currently serves on the Federal Government’s Biomedical Translation Fund Committee.

Prof David Wood

Professor David Wood came to Australia from England following a Fellowship at Harvard and the University of Florida, Gainesville.  He has had a long standing interest in orthopaedic oncology and was elected Chairman of the Western Australian Bone Tumour Registry in 1994, and the first chair of the West Australia Sarcoma Multidisciplinary Group.

 

Prof Wood  has been a visiting Professor at a number of international institutions including The University of Florida Gainesville, Sun Yet Sen University Guangzhou, the Chinese University of Hong Kong , The National University of Singapore, The Royal National Orthopaedic Hospital London and Oxford University. 

 

  He recently completed a sabbatical at Cambridge University’s Sanger Genome Institute and works to foster collaborative research to improve the outcomes for sarcoma patients.

Prof Ross Baker

Professor Ross Baker is currently Directorof the WA Centre for Thrombosis and Haemostasis, Murdoch University and Director of Medical Services – Western Haematology and Oncology Clinics.

 

He is an active clinician scientist and has authored over 116 peer-reviewed papers in academic journals and beenactively involved in more than 125 clinical trials.

 

He is currently chairman of two large academic multi-centre collaborative research studies in Asia – Pacific, Australia and New Zealand with over 40 sites involved. His research interests include new treatments of patients with leukaemia, lymphoma, myeloma, thrombocytopenia, haemophilia, solid tumour cancers and brain tumours. He is currently is the founding Chairman of the Perth Blood Institute (PBI), a not for profit research organisation which currently employees 20 doctors, scientists and health professionals. PBI performs basic laboratory research for new drug discovery and it has successfully co-ordinated over 50 clinical trials and research studies since inception in 2013.

Dr Chris Denz

Dr Chris Denz graduated from the Otago Medical School in 1983 and has been involved in general practice in Perth for over thirty years. He founded one of Perth’s largest and most active central city medical centres in the late 1980s.

 

He has served as primary care physician for numerous cancer patients over three decades liaising with oncologists, surgeons, radiologists and hospitals with the goal of achieving the best possible outcomes for his patients. In 2013 he was diagnosed with throat cancer and embarked on the same journey as many of his patients undergoing extensive chemotherapy, radiotherapy and then recovery before returning to medical practice in 2014.

 

As a consequence of his illness Chris has gained an even deeper appreciation of the challenges facing cancer patients and is committed to improving patient outcomes in the oncology area. He is encouraged by the recent advances in cancer immunotherapy and views immunotherapies as promising and potentially less damaging treatment options for many of his patients.